Related Experiment Videos
[Topotecan for pediatric patients with resistant and recurrent solid tumors]
A Pérez Martínez1, T Contra, C Scaglione
1Servicio de Oncología Infantil. Hospital del Niño Jesús. Madrid. España. antonioperezmartinez@yahoo.es
Anales De Pediatria (Barcelona, Spain : 2003)
|July 29, 2003
Summary
Topotecan shows promise in treating pediatric refractory solid tumors, particularly neuroblastomas and soft tissue sarcomas. Hematological toxicity was manageable, suggesting potential for further therapeutic strategies.
Area of Science:
- Oncology
- Pharmacology
Context:
- Topotecan, a DNA topoisomerase I inhibitor, is explored for pediatric cancer treatment.
- Evaluating topotecan's efficacy in second-line treatment for refractory pediatric solid tumors.
Purpose:
- Assess preliminary experience with topotecan in pediatric refractory solid tumors.
- Investigate topotecan's effectiveness as a monotherapy or in combination regimens.
Summary:
- Retrospective study included 10 pediatric patients with recurrent/refractory solid tumors.
- Five patients demonstrated favorable responses (complete, partial, or stable disease).
- All patients experienced manageable hematological toxicity (grade II-IV).
Impact:
- Topotecan shows benefit in specific refractory/recurrent pediatric solid tumors, notably neuroblastomas and soft tissue sarcomas.
- Myelosuppression was tolerable with growth factor support.
- Complete responders may benefit from high-dose chemotherapy and stem cell rescue.